Zacks Research Issues Negative Outlook for JAZZ Earnings

Key Points

• Zacks Research lowered its Q3 2026 EPS estimate for Jazz Pharmaceuticals to $5.35 from $5.49 and projects FY2026 EPS of $20.77, signaling a more cautious earnings outlook.
• Jazz’s latest quarter showed mixed results: EPS of $5.71 missed the $6.18 consensus, while revenue of $1.21 billion exceeded estimates and rose 15.5% year over year.
• Despite the earnings concerns, analyst sentiment remains favorable, with an average “Buy” rating and a $279 price target versus the stock’s $249.29 opening price; FDA approval expanding Ziihera’s market is a key positive catalyst, while a $1 billion exchangeable-notes offering adds leverage and potential dilution risk.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) - Stock analysts at Zacks Research reduced their Q3 2026 earnings per share estimates for Jazz Pharmaceuticals in a report issued on Monday, August 24th. Zacks Research analyst Team now expects that the specialty pharmaceutical company will earn $5.35 per share for the quarter, down from their previous estimate of $5.49. The consensus estimate for Jazz Pharmaceuticals' current full-year earnings is $21.66 per share. Zacks Research also issued estimates for Jazz Pharmaceuticals' Q4 2026 earnings at $5.29 EPS, FY2026 earnings at $20.77 EPS, Q1 2027 earnings at $4.30 EPS, Q2 2027 earnings at $5.44 EPS, Q3 2027 earnings at $5.16 EPS, Q4 2027 earnings at $5.12 EPS, FY2027 earnings at $20.02 EPS, Q1 2028 earnings at $4.92 EPS, Q2 2028 earnings at $6.09 EPS and FY2028 earnings at $22.74 EPS.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.18 by ($0.47). Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. The firm had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.11 billion. During the same quarter in the previous year, the firm earned ($8.25) earnings per share. The business's quarterly revenue was up 15.5% compared to the same quarter last year.

Several other equities research analysts also recently commented on the stock. Wells Fargo & Company upped their price objective on shares of Jazz Pharmaceuticals from $285.00 to $300.00 and gave the company an "overweight" rating in a report on Tuesday, August 4th. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Jazz Pharmaceuticals from $287.00 to $300.00 and gave the stock a "buy" rating in a research note on Wednesday. Robert W. Baird upped their price target on shares of Jazz Pharmaceuticals from $252.00 to $280.00 and gave the company an "outperform" rating in a research note on Tuesday, August 4th. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $277.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday. Finally, Needham & Company LLC lifted their price objective on shares of Jazz Pharmaceuticals from $292.00 to $310.00 and gave the company a "buy" rating in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $279.00.

Jazz Pharmaceuticals Stock Down 4.2%

JAZZ stock opened at $249.29 on Thursday. The stock has a fifty day moving average of $246.38 and a 200-day moving average of $217.52. Jazz Pharmaceuticals has a fifty-two week low of $123.87 and a fifty-two week high of $266.38. The company has a market capitalization of $16.18 billion, a price-to-earnings ratio of 17.19, a PEG ratio of 0.23 and a beta of 0.32. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.58 and a current ratio of 1.78.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in JAZZ. California State Teachers Retirement System raised its position in shares of Jazz Pharmaceuticals by 24,585.6% in the second quarter. California State Teachers Retirement System now owns 15,714,136 shares of the specialty pharmaceutical company's stock worth $3,786,635,000 after buying an additional 15,650,479 shares in the last quarter. Capital World Investors grew its position in Jazz Pharmaceuticals by 4.4% during the fourth quarter. Capital World Investors now owns 2,666,602 shares of the specialty pharmaceutical company's stock worth $453,322,000 after buying an additional 111,735 shares in the last quarter. Ameriprise Financial Inc. grew its position in Jazz Pharmaceuticals by 11.4% during the second quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company's stock worth $198,159,000 after buying an additional 191,637 shares in the last quarter. Franklin Resources Inc. increased its stake in Jazz Pharmaceuticals by 164.0% in the 4th quarter. Franklin Resources Inc. now owns 1,818,911 shares of the specialty pharmaceutical company's stock worth $309,215,000 after acquiring an additional 1,129,995 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in Jazz Pharmaceuticals by 44.5% in the 1st quarter. Bank of New York Mellon Corp now owns 1,679,371 shares of the specialty pharmaceutical company's stock worth $317,485,000 after acquiring an additional 517,514 shares during the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Neena M. Patil sold 1,200 shares of the company's stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $231.83, for a total transaction of $278,196.00. Following the sale, the executive vice president directly owned 51,549 shares in the company, valued at $11,950,604.67. This represents a 2.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Bruce C. Cozadd sold 6,000 shares of the stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $252.98, for a total transaction of $1,517,880.00. Following the completion of the sale, the director directly owned 360,682 shares in the company, valued at approximately $91,245,332.36. The trade was a 1.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 14,357 shares of company stock worth $3,505,642 over the last ninety days. Company insiders own 4.10% of the company's stock.

Key Headlines Impacting Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: The FDA approved two Ziihera (zanidatamab-hrii) regimens for first-line treatment of adults with unresectable, locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma. The approval covers Ziihera with tislelizumab and chemotherapy for all eligible HER2-positive patients, as well as Ziihera with chemotherapy for a narrower subgroup. The expanded indication substantially increases Ziihera’s addressable market and could support blockbuster sales. FDA Ziihera approval
• Positive Sentiment: Analysts raised their price targets following the approval. Needham lifted its target to $310 from $292 and maintained a Buy rating, while Truist raised its target to $281 from $264 and also rated the stock Buy. The revisions indicate increased expectations for Ziihera’s revenue contribution and Jazz’s growth outlook. Analyst price-target increases
• Neutral Sentiment: Brokerage coverage remains broadly favorable, with Jazz receiving an average Buy recommendation. However, the rating may already reflect some of the optimism surrounding Ziihera’s approval. Average Buy recommendation
• Negative Sentiment: Jazz announced a private offering of $1.0 billion of exchangeable senior notes due 2032, with an option for purchasers to acquire an additional $150 million. Although the proceeds are intended to support concurrent ordinary-share repurchases, the financing increases leverage and creates potential future share dilution, weighing on the stock’s near-term reaction. Exchangeable-notes offering

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company's research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz's product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source